351 related articles for article (PubMed ID: 7333326)
1. Saliva and plasma clearance of antipyrine as reflectors of liver function.
Luoma PV; Sotaniemi EA
Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
[TBL] [Abstract][Full Text] [Related]
2. Salivary antipyrine kinetics in hepatic and renal disease and in patients on anticonvulsant therapy.
Harman AW; Penhall RK; Priestly BG; Frewin DB; Phillips PJ; Clarkson AR
Aust N Z J Med; 1977 Aug; 7(4):385-90. PubMed ID: 270989
[TBL] [Abstract][Full Text] [Related]
3. Antipyrine kinetics in liver disease and liver transplantation.
Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
[TBL] [Abstract][Full Text] [Related]
4. A comparative study of antipyrine pharmacokinetics in saliva and plasma using a colourimetric method of antipyrine analysis.
Harman AE; Priestly BG; Frewin DB
Clin Exp Pharmacol Physiol; 1977; 4(6):593-6. PubMed ID: 589875
[TBL] [Abstract][Full Text] [Related]
5. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic lever disease.
Branch RA; James JA; Read AE
Clin Pharmacol Ther; 1976 Jul; 20(1):81-9. PubMed ID: 1277728
[TBL] [Abstract][Full Text] [Related]
6. Antipyrine clearance per unit volume liver: an assessment of hepatic function in chronic liver disease.
Homeida M; Roberts CJ; Halliwell M; Read AE; Branch RA
Gut; 1979 Jul; 20(7):596-601. PubMed ID: 488757
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of hepatic drug metabolism by glutethimide in patients with liver disease.
Farrell GC; Cooksley WG; Powell LW
Eur J Clin Pharmacol; 1979 Sep; 16(2):113-7. PubMed ID: 499307
[TBL] [Abstract][Full Text] [Related]
8. Elimination of antipyrine from saliva as a measure of metabolism in man.
Welch RM; DeAngelis RL; Wingfield M; Farmer TW
Clin Pharmacol Ther; 1975 Sep; 18(3):249-58. PubMed ID: 1164815
[TBL] [Abstract][Full Text] [Related]
9. Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.
Vesell ES; Passananti GT; Glenwright PA; Dvorchik BH
Clin Pharmacol Ther; 1975 Sep; 18(3):259-72. PubMed ID: 1164816
[TBL] [Abstract][Full Text] [Related]
10. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the half-life of antipyrine in plasma, whole blood and saliva of man.
van Boxtel CJ; Wilson JT; Lindgren S; Sjöqvist F
Eur J Clin Pharmacol; 1976 Feb; 9(4):327-32. PubMed ID: 971716
[TBL] [Abstract][Full Text] [Related]
12. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
Farrell GC; Zaluzny L
Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
[TBL] [Abstract][Full Text] [Related]
13. [An attempt at assessment of biotransformation activity in calves' liver on the basis of the rate of antipyrine elimination from saliva].
Janus K; Baranow-Baranowski S; Jakubowska D
Pol Arch Weter; 1991; 31(3-4):65-71. PubMed ID: 1842615
[TBL] [Abstract][Full Text] [Related]
14. Antipyrine metabolite kinetics in healthy human volunteers during multiple dosing of phenytoin and carbamazepine.
Shaw PN; Houston JB; Rowland M; Hopkins K; Thiercelin JF; Morselli PL
Br J Clin Pharmacol; 1985 Dec; 20(6):611-8. PubMed ID: 4091993
[TBL] [Abstract][Full Text] [Related]
15. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
von Mandach U; Jost G; Preisig R
Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
[TBL] [Abstract][Full Text] [Related]
16. Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone.
Rautio A; Kauppila AJ; Tuimala RJ; Sotaniemi EA
Biomedicine; 1979 Sep; 31(5):135-8. PubMed ID: 508896
[TBL] [Abstract][Full Text] [Related]
17. Assessment of antipyrine kinetics by measurement in saliva.
Fraser HS; Mucklow JC; Murray S; Davies DS
Br J Clin Pharmacol; 1976 Apr; 3(2):321-5. PubMed ID: 973966
[TBL] [Abstract][Full Text] [Related]
18. Assessment of antipyrine kinetics from saliva or plasma: influence of age.
Jorquera F; Almar MM; Jimeno A; González-Sastre M; González-Gallego J
J Pharm Biomed Anal; 1995 Aug; 13(9):1141-5. PubMed ID: 8573640
[TBL] [Abstract][Full Text] [Related]
19. Application of salivary concentration data to pharmacokinetic studies with antipyrine.
Meffin PJ; Williams RL; Blaschke TF; Rowland M
J Pharm Sci; 1977 Jan; 66(1):135-7. PubMed ID: 833730
[TBL] [Abstract][Full Text] [Related]
20. Impairment of hepatic drug metabolism in alcoholics.
Harman AW; Frewin DB; Priestly BG; Alexander CB
Br J Clin Pharmacol; 1979 Jan; 7(1):45-8. PubMed ID: 760741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
